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Alkylating agents are frequently used in many established anticancer chemotherapies. They alkylate the ge-
nomic DNA at various sites. Alkylation of the guanine at the O6-position is cytotoxic, it has the strongest muta-
genic potential, as well as can cause the tumor development. Alkyl groups at the O6-position of guanine are remo-
ved by the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT). The effectiveness of alkyla-
ting chemotherapy is limited by MGMT in cancer cells and adverse toxic side effects in normal cells. Different
approaches consisting in the modulation of the MGMT expression and activity are under development now to im- 
prove the cancer chemotherapy. They include two main directions, in particular, the increase in chemosen-
sitivity of cancer cells to alkylating drugs and the protection of normal cells from the toxic side effects of che-
motherapy. This review is focused on current attempts to improve the alkylating chemotherapy of malignant tu-
mours worldwide and state of the issue in Ukraine. 
Keywords: cancer chemotherapy, strategies of chemotherapy improvement, alkylating agents, O6-methylguani-
ne-DNA methyltransferase (MGMT), DNA repair. 
Introduction. Alkylating agents are frequently used
in the anticancer chemotherapy. These agents alkylate 
the genomic DNA at various sites [1]. Alkylation of the
guanine at the O6-position is cytotoxic, it has the stron-
gest mutagenic potential as well as can cause the tu-
mor development [1, 2]. Different pathways of DNA
repair are evolved in mammalian cells for self-defense 
against toxic and mutagenic effects, namely direct re-
versal repair, mismatch repair (MMR), nucleotide and 
base excision repair, as well as repair of double-strand
DNA breaks and interstrand cross-links by homolo-
gous recombination and non-homologous end joining
[3–5]. DNA adducts at the O6-position of guanine (such
as methyl-, ethyl-, chloroethyl-group a. o.) of mam-
malian DNA are removed by the DNA repair enzyme
O6-methylguanine-DNA methyltransferase (MGMT). 
This DNA repair enzyme belongs to the direct repair
pathway, i. e. removes alkyl groups without DNA le-
sion, transferring them to an own cysteine residue by the
mechanism of so-called «suicidal» reaction [1, 2]. The
capacity of cells to repair the O6-alkylguanine depends
on the levels of expression and activity of MGMT in cell 
or on the rate at which a cell can synthesize this enzyme.
Thus, the activity of this alkyltransferase is the most im-
portant factor of the cell sensibility to cytotoxic and mu-
tagenic effects of the alkylation, but just MGMT is one
of the causes of tumor cell resistance to specific alkyla-
ting agents of chemotherapeutic drugs. Therefore, the
MGMT is considered as one of the molecular marker for
the prediction of the efficiency of  the chemotherapeutic
treatment of cancer cells. Different approaches of consis-
ting in the modulation of the MGMT expression and acti-
vity have been developing now to improve the efficacy
of cancer chemotherapy by alkylating agents and to redu-
ce its toxic side effects. 
For example, the MGMT gene transcription silen-
cing, RNA interference, and the MGMT enzyme inacti-
vation are among strategies to increase the sensitivity of
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cancer cells to alkylating drugs, while the drug dose re-
duction, the local drug administration, and the myelo-
protective gene therapy are used for the protection of bo- 
ne marrow cells from these drugs.
This review is focused on current attempts to impro-
ve the alkylating chemotherapy of malignant tumours
in the world and state of this issue in Ukraine.
Alkylating agents and cancer therapy. Alkyla-
ting agents are classified into several groups, namely
into classical, non-classical and alkylating-like agents
(Table). Among classical alkylating agents with true
alkyl groups are nitrosoureas, which are often used in
chemotherapy of brain tumors, because they have lipo-
philic properties and thus can cross the blood-brain bar- 
rier. Methylating and chloroethylating nitrosoureas ha- 
ve a strong cytotoxic effect on dividing cells causing
the apoptotic cell death induced by the O6-alkylguani-
ne, but the using of such type of medicine is non-effec-
tive in many cases because of the DNA repair by the
MGMT enzyme.
A list of antineoplastic alkylating drugs approved for
the use in Ukraine in therapy of different types of can-
cer by the order of Ministry of Health of Ukraine is gi-
ven in the State form of medicines (# 173, March 17,
2009). This list is based on the previous order of Minis-
try of Health of Ukraine (# 514, September 05, 2008),
but contains some changes and the information about
interaction with other medicines and some features of
drug use, in particular, main pharmacotherapeutic ef-
fects, indications for the use, modes and doses, side ef-
fects and complications, contraindications etc. (# 173,
March 17, 2009). The medicines that are allowed for
using in the cancer therapy in Ukraine are highlighted
in bold in the Table.
Many established cancer therapies involve the DNA
damage radiotherapy and/or chemotherapy, in which
different alkylating agents are used alone or in combi-
nation with other agents as the antineoplastic drugs.
They have the ability to alkylate many nucleophilic func-
tional groups under conditions existing in the cells, che-
mically modifying the DNA, RNA and proteins, im-
pairing in such way biologically important cell func-
tions [1]. The alkylating agent effectiveness is limited
by adverse toxic side effects for normal cells, which de- 
fines maximum tolerated doses, especially for the cells
that propagate frequently, for example the cells of bone 
marrow, gastrointestinal tract, testicles and ovaries.
Another major clinical barrier for the successful an- 
ticancer therapy is the inherent or treatment-induced re-
sistance of tumor cells to the chemotherapeutic agents.
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Classical alkylating agents
Non-classical agents
Alkylating-like agents
(platinum analogues)*Nitrogen mustards Nitrosoureas Alkyl sulfonates
Cyclophosphamide Methylating agents Busulfan Altretamine Cisplatin
Mechlorethamine (or mustine)    Dacarbazine (DTIC)* – – Carboplatin
Uramustine (or uracil mustard)    Procarbazine – – Nedaplatin
Melphalan    Streptozocin – – Oxaliplatin
Chlorambucil    Temozolomide (TMZ)* – – Satraplatin
Ifosfamide Chloroethylating agents – – Triplatin tetranitrate
Thiotepa    Nimustine (ACNU) – – –
–    Carmustine (BCNU) – – –
–     Lomustine (CCNU) – – –
–    Semustine (MeCCNU) – – –
–    Fotemustine – – –
*The platinum analogues, as well as the tetrazines (dacarbazine, temozolomide) are sometimes described as non-classical. The agents allowed to
use in Ukraine are highlighted in bold [4, 5].
The alkylating agents used in the chemotherapy as anticancer drugs
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The effectiveness of antineoplastic agents is dependent
not only on an appropriate choice of drugs at certain ty-
pe of cancer and scheme of therapy, but also on diffe-
rent DNA repair systems. For example, as abovemen-
tioned, the MGMT can cause the resistance of cancer
cells to alkylating agents via direct repair of the O6-al-
kylguanine. The effectiveness of anticancer therapy de- 
pends also on the activity of post-replication MMR sys-
tem (in case of the methylating agents) or other systems 
of the DNA repair and recombination (in case of the chlo-
roethylating agents) [1]. The resistance of cancer cells
to alkylating agents can be caused also by repeated treat-
ment with a drug. Such acquired resistance is frequent-
ly observed in tumor therapy, in particular in melano-
ma treatment with fotemustine [6], glioma – with temo- 
zolomide (TMZ) [7, 8]. It has been shown on the cell
line models that the glioma cells, acquired resistance to
TMZ, had at least two different mechanisms consistent
with clinical observations, namely the MGMT re-exp-
ression or MMR inactivation and the recruitment of
key base excision repair enzymes [9]. For the exten-
sive review on mechanisms of chemoresistance of ma-
lignant glioma cells see [10].
It has been observed that the MGMT promoter me-
thylation is correlated with a better outcome of alkyla-
ting agent therapy of malignant brain tumors and pro-
longed survival of patients [11] suggesting the MGMT
promoter methylation status is a predictive marker for
clinical outcome in glioma therapy [12]. However, it has
been revealed in clinical trial of TMZ in advanced ma-
lignant melanoma that pretreatment levels of MGMT in 
melanoma cells did not predict the clinical response to
TMZ [13], assuming probably a higher frequency of re- 
inactivation of the MGMT expression in melanoma
cells. Thus, MGMT is one of the most important factors 
of normal and cancer cell sensitivity and response to the
alkylating drugs that can cause the chemoresistance.
The examination of the MGMT promoter methyla-
tion status and/or the MGMT expression level together
with the p53 expression analysis in tumors are impor-
tant steps in individual approach to the choice of alkyla-
ting agents and clinical protocols of the treatment of glio-
mas and malignant melanomas. As mentioned above,
such approach is used in the chemotherapy of malignant
brain tumors. However, this diagnostics, unfortunately,
is not being carried out in Ukraine. Analysing the recom- 
mended schemes of the treatment of main cancer types
in adults (# 554, September 17, 2007 and # 645, July 30,
2010) and children (# 649, August 28, 2009 and # 618,
July 23, 2010), it should be mentioned that for today in
normative documents of Ministry of Health of Ukraine
there is no a single recommendation for the analysis of
the MGMT expression and/or methylation of its promo- 
ter. It is not considered even as an additional survey,
which can be conducted at presence of the sufficient
supply of materials and machinery or at patients cost at
their desire, in valid for today normative documents of
Ministry of Health of Ukraine.
Approaches to improve the chemotherapy of can- 
cer. Taking into consideration the above outlined bar-
riers of the to successful treatment of malignant tumors
by alkylating agents, different approaches of the modu- 
lation of the MGMT expression and the enzyme activi-
ty are developing now as possible strategies of the che-
motherapy improvement. They include two main direc-
tions, in particular, the MGMT inactivation in cancer
cells to increase the chemotherapy efficiency, and the
MGMT activation in bone marrow cells or local drug
administration to protect normal cells from the toxic ef- 
fect of alkylation agents (Figure).
The increase in tumor cell sensitivity to alkyla-
ting drugs. Silencing of the MGMT gene (repression of 
the transcription), silencing of the MGMT protein bio-
synthesis (RNA interference), and the MGMT enzyme
inactivation belong to strategies to increase the sensiti-
vity of cancer cells to alkylating drugs (Figure).
The repression of the MGMT gene transcription
can be achieved in different ways, for example by using 
transcription factors, epigenetic changes of the gene pro-
moter region, the gene body or chromatin. However, it
will be difficult to implement these approaches in clinic 
due to the lack of knowledge about the subtle mecha-
nisms of transcription regulation of the MGMT gene
and consequences of their clinical use.
Oncolytic viruses possess an inherent tropism to tu- 
mour cells, so they are being investigated for selective
replication in cancer cells and their destruction. Some
academic labs and companies work with adenovirus or
other viruses to study a viral therapy of cancer [14, 15].
It has been shown that the E1A gene product of adeno-
virus efficiently down-regulates MGMT due to the pre-
vention of p300 from the recruitment to the MGMT pro-
moter and may thus reduce chemoresistance, sugges-
ting a possibility of the combined chemotherapy and
viral therapy [7, 8]. The first viral therapy of cancer in
the world was approved for research in China several
years ago and passed the phase I to phase III clinical
trials for treating head and neck cancer [14, 16]. Seve-
ral recombinant vaccinia virus products for cancer the-
rapy have been also developed by Jennerex Biothera-
peutics Inc. company (USA).
In spite of up-and-coming prospects of viral therapi-
es, the main obstacle is the human adaptive immune res-
ponse and virulent strains that arised and did not dissa-
pear during viral replication in tumours.
The RNA interference (RNAi) as a technology to si-
lence gene expression can be also used to silence the
MGMT gene. It has been shown that transfection of in
vitro cultivated cells with the MGMT-targeted short-
interfering RNA increased cell sensitivity to alkylating
agents, for example human nasopharyngeal carcinoma
HONE-1 cells to carmustine (BCNU) [17] and malig-
nant glioma cells to TMZ [18]. It is suggested the clini-
cal use of the RNAi strategy to sensitize cancer cells to
the alkylating drugs. However, among significant prob-
lems, which prevent the in vivo RNAi application targe-
ted to MGMT, are incomplete silencing of a target gene 
and so-called off-target effects, non-specific immune
responses, and a major challenge – in vivo delivery.
The depletion of MGMT. The MGMT enzyme may 
be inactivated in two ways, namely by using the alkyla- 
ting agents which inactivate this enzyme indirectly via
the direct reversal DNA repair, as well directly by using
the low-molecular MGMT inhibitors.
The dose-dense schedules of cancer chemotherapy
and combinations of the alkylating agents have been
studied as strategies to deplete the MGMT enzyme and
increase cancer cell sensitivity to the chemotherapy.
The dose-dense regimen was considered as one of the
most important tools in the conventional chemotherapy 
of patients with potentially curable malignancies [19].
The data on efficacy, safety and toxic side effects of
dose-dense TMZ regimens in patients with recurrent
glioma and advanced metastatic melanoma are revie-
wed in [20]. A proper drug combination can also dep-
lete MGMT. For example, it has been shown that me-
thylating agents are able to reduce the MGMT activity
prior to the administration of chloroethylating agents.
However, the high-intensive chemotherapy causes the
MGMT depletion not only in tumor cells, but also in
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Drug dose reduction (due to combinations
of the alkylating agents and the MGMT
inhibitors use)
Local drug administration (targeting of the
MGMT inhibitors and alkylating agents) Myeloprotective gene therapy
APPROACHES TO IMPROVE THE CANCER CHEMOTHERAPY BY USING ALKYLATING AGENTS
To protect normal cells (e. g. bone marrow cells)
To increase cancer cells sensitivity to alkylating drugs
Repression of the MGMT gene
transcription (by using a viral cancer
therapy, transcription factors, epigenetic
changes of the promoter, the gene body
or chromatin)
Silencing of the MGMT protein
biosynthesis (e. g. RNA interference)
The MGMT depletion (by using dose-dense
regimens of chemotherapy, combinations of
alkylating agents, MGMT inhibitors)
Different strategies of two main approaches to improve the cancer chemotherapy by using alkylating drugs
normal cells, thus increasing toxic side effects, in par-
ticular myelosuppression and therapy-related secon-
dary tumours (see below) [21].
The MGMT activity can be blocked by inhibitors
of this enzyme, low molecular weight pseudosubstra-
tes, used prior to the alkylating agent chemotherapy
[22]. Among the MGMT inhibitors are analogues of the 
O6-methylguanine in DNA, namely the O6-benzylgua-
nine (O6-BG) and the O6-(4-bromothenyl)guanine (Lo-
meguatrib, LM, Patrin, PaTrin-2).
It has been shown in human tumour cell lines, xeno-
graft models of different cancer types, as well as in cli-
nical trials that inactivation of MGMT by the pseudo-
substrate inhibitors sensitizes tumour cells to the alkyla-
ting and alkylating-like agents [23, 24]. The chemothe-
rapy regimens of O6-BG in combination with BCNU,
TMZ and Gliadel® (wafer of polifeprosan 20 with
BCNU) are in clinical development. 
Now, the Phases I and II of several clinical trials of
the O6-BG and BCNU or TMZ combination are comp-
leted, and the Phases II and III are still ongoing in brain
tumors, colon cancer, lymphoma, melanoma or sarco-
ma. For instance, the Phase I clinical trial of coadmini-
stration of O6-BG and BCNU was conducted in USA in
the patients with advanced solid tumors (malignant
gliomas, melanomas) and with lymphoma [25]. Also,
the combination of a bolus injection of O6-BG with im-
planted Gliadel® wafers in adult patients with recurrent
glioblastoma multiforme improved the efficacy of im-
planted Gliadel® wafers in the Phase II trial [26]. In
another Phase II clinical trial, the coadministration of
O6-BG with TMZ has been studied in the patients with
progressive malignant glioma (USA) [27]. Though the
use of O6-BG gave a possibility to reduce a dose of al-
kylating drug, it causes primary bone marrow sup-
pression which may be cumulative in the combination
with alkylating drug, so other pseudosubstrates of the
MGMT enzyme are currently being developed and in-
vestigated.
LM is another MGMT pseudosubstrate, which is less
toxic and more potent inactivator of this enzyme, than
O6-BG. The inhibitory activity of LM has been shown
in preclinical studies, in particular in human primary
cells, tumor cell lines and xenograft models including
breast tumors [28], acute leukaemia [29], melanoma
[30], ovarian cancer [31], as well as in clinical trials.
The Phase I clinical trials of combined TMZ and LM
treatment of the patients with melanoma conducted at
Christie Hospital and at University College have been
completed (London, U. K.) [32] and now the Phase II
trials are ongoing. Also, there was conducted another
randomized trial of the LM-TMZ combination in che-
motherapy of the patients with metastatic unresectable
stage III or IV cutaneous melanoma [33].
The LM-TMZ combination in treatment of patients
with inoperable stage IV metastatic colorectal carcino-
ma has been shown to be inefficient in a multi-centre
Phase II clinical trial conducted in U. K. (Christie and
Churchill Hospitals) and Australia (8 centres) [34].
However, the therapy of patients with metastatic colo-
rectal cancer using a combination of LM and irinote-
can (the Phase I trial) was more successful [35]. No ad-
vantage of the combined therapy by LM-TMZ over con-
ventional TMZ administration has been also observed
in the Phase I study melanoma treatment in the pati-
ents with advanced unresectable stage III or IV cutane-
ous or unknown primary melanoma metastases [36].
LM is also being trialled in USA in combination
with dacarbazine for melanoma and in Italy in combi-
nation with TMZ for leukaemia treatment (data on web-
site of Carcinogenesis group, Paterson Institute for Can-
cer Research, The University of Manchester, U. K.).
However, it has been revealed that the systemic ad-
ministration of O6-BG-based inhibitors of MGMT and
their combination with alkylating agents causes deple-
tion of MGMT in all tissues of the body enhancing the
cytotoxicity and the induction of GC to AT transition
mutations presumably in stem cells, so the strategies to
protect normal cells during the cancer chemotherapy are
also being investigated.
The reduction of toxic side effects of alkylating
drugs. It is known that the alkylating agents have toxic
side effects in normal cells that divide frequently. The-
se agents can cause secondary tumors, for example, leu-
kemia. Their carcinogenic role has been shown in ani-
mal models, as well in clinical studies [21]. The acute
myeloid leukemia is the most frequent late complica-
tion of the alkylating agent chemotherapy and/or radio- 
therapy, as well as the chemotherapy with topoisome-
rase-II-inhibitors and antimetabolites [21, 37]. Thus, a
decrease in a toxic side effect of drugs is an important
task in cancer therapy. Drug dose reduction, local drug
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administration, and myeloprotective gene therapy are
among the strategies of the protection of bone marrow
cells from alkylating drugs (Figure).
The dose reduction of alkylating drugs can be achie-
ved by coadministration with the MGMT inhibitors. For
more details see above «The depletion of the MGMT».
In the strategy of the local drug administration an
alkylating agent alone or in combination with the
MGMT inhibitor, for example O6-BG, is administered
directly into the tumour area to reduce the drug toxicity
to the organism. Several approaches to melanoma the-
rapy have been developed in animal model and studied
in clinic. It has been shown in a rat model that the con-
comitant application of hyperthermia during an isola-
ted limb infusion of TMZ has improved the efficacy of
melanoma therapy [38]. A significant improvement of
melanoma antitumor responses with a tumour growth
delay and minimal toxicity has been also shown in ano-
ther study of regional therapy of human melanoma xe-
nografts of the extremity in nude rats by using paren-
teral TMZ administration in conjunction with O6-BG
[39]. In the same animal model it has been shown that
therapy with a regional infusion of TMZ was more ef-
fective for the xenograft with the lowest MGMT acti-
vity than melphalan which was more effective at the hi- 
ghest MGMT activity [40].
To optimize the response of recurrent melanoma of
human extremity and to minimize drug toxicity to nor-
mal cells it has been used a regional therapy with two
procedures, namely hyperthermic isolated limb perfu-
sion and isolated limb infusion [41]. This therapy pro-
vides a way to deliver a chemotherapy drug locally to
extremity in a higher dose.
The local administration of alkylating drug into the
area after tumour resection in combination with a syste- 
mic infusion of O6-BG [42, 26] and the intracerebral ad-
ministration of O6-BG combined with systemic chemo- 
therapy with TMZ [43] are new strategies of the local
brain tumour therapy. In the Phase I trial held in USA
the optimal dose of O6-BG coadministered intrave-
nously as a continuous infusion with intracranially im-
planted Gliadel® wafers has been studied in adult pati-
ents with recurrent malignant glioma [42]. In the Phase
II trial of Gliadel® wafers it has been shown that a sys-
temic administration of O6-BG can have side effects,
among which an increased risk of hydrocephalus, cere-
brospinal fluid leak, and cerebrospinal fluid/brain infec-
tion despite the therapy efficacy improvement [26]. In
another study of systemic chemotherapy of recurrent
glioblastoma with TMZ, local MGMT inactivation has
been achieved by the intracerebral administration of
O6-BG in the tumour cavity [43]. It has been shown that 
this strategy might be safe for improving glioma the-
rapy without increasing drug-induced systemic toxic si-
de effects.
Different strategies of the myeloprotective gene the-
rapy have been studied to increase the level of the
MGMT expression in peripheral mononuclear blood
cells [44]. Among them is the ex vivo transduction of he- 
matopoietic stem cells transfected by the vectors exp-
ressing mutant forms of the MGMT protein coupled
with the simultaneous use of pharmacologic MGMT in-
hibitors and alkylating drugs [44, 45]. Such mutant
MGMT proteins (e. g. G156A, P140K) are resistant to
the inactivation by pseudosubstrates, such as O6-BG,
LM. This innovative approach in the cancer chemo-
therapy has a main goal to protect hematopoietic cells
and enhance the DNA repair activity by stably integra-
ting gene vectors that express MGMT. Therefore, the
potent expression cassettes have been designed which
can be used as potentially useful in the clinic MGMT
vectors, an important component of which is formed by 
active enhancer sequences. However, it has been revea- 
led that the vectors with strong enhancers are more li-
kely to induce adverse events related to insertional mu-
tagenesis [45]. Also, it is suggested that in the absence
of alkylating agents high expression of the P140K mu-
tant can induce a selective disadvantage. Considering
these observations, now the attempts to generate clini-
cally useful and safe MGMT vectors have being done.
The defence of bone marrow-derived hematopoie-
tic progenitors from toxic side effects of the chemothe-
rapeutic alkylating drugs (for example BCNU or TMZ) 
and O6-BG by using oncoretroviral transduction of the
mutant form of MGMTG156A into mouse and human he-
matopoietic progenitors has been presented in early pa- 
pers devoted to the myeloprotective gene therapy [46–
48]. However, it has been shown that hematopoietic
stem cells expressing the P140K mutant form of MGMT
were more O6-BG-resistant under stringent drug-selec-
tion competition than the G156A [49]. So, the papers
about the mouse model of transplantation of hemato-
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poietic stem cells transfected by vectors expressing the
P140K appeared a few years later [50, 51]. It has been
found that the retroviral co-expression of the P140K
with either p-glycoprotein or multidrug resistance-re-
lated protein 1 may provide an effective in vivo protec-
tion of hematopoietic cells during the cancer chemothe-
rapy [52]. An increased protective effect of the simul-
taneous overexpression of the multidrug resistance-re-
lated protein 1 and the P140K has been also shown in a
more recent study [53]. A bicistronic lentiviral vector
overexpressing these two drug-resistance genes provi-
ded the protection of leukemia cell line HL60 against
O6-BG and nimustine (ACNU) plus paclitaxel therapy
as well as the protection of human hematopoietic
CD34+ stem cells against both monotherapy with O6-
BG-TMZ and combined therapy with O6-BG-TMZ plus
paclitaxel.
Since self-inactivating retroviral vectors lacking en-
hancer-promoter sequences in the long terminal repeats 
were related to insertional mutagenesis, it has been stu-
died the potency of gammaretroviral and lentiviral vec- 
tors expressing the P140K mutant under control of en-
hancer-promoter sequences located either in the long
terminal repeat or downstream of the packaging region
to internal initiation of transcription from self-inacti-
vating backbones [54]. It has been revealed that gam-
maretroviral vectors with intact long terminal repeats
containing enhancer-promoter sequences showed both
higher titres and higher expression levels than the len-
tiviral counterparts, as well as a higher transduction ef-
ficiency on proliferating human CD34+ cells [54]. The
potential utility of lentiviral vectors for the drug-resis-
tant gene transfer to human hematopoietic stem cells
for in vivo selection and marrow protection has been
studied because of their enhanced ability to transduce
nondividing cells [55]. The use of the P140K provided
efficient post-transduction selection of human cells
using lentivirus under low-multiplicity of infection con-
ditions that did not require cytokine stimulation or viral 
concentration, and the therapeutic drug combination of
BCNU and O6-BG [55].
Besides, it has been shown a possibility to transfer
the P140K into long-term repopulating hematopoietic
stem cells by using foamy virus, because such systems
may integrate in the positions that modulate host gene
expression to a less extent than oncoretroviral or len-
tiviral vectors [56]. The expression of P140K under
control of weaker promoter/enhancers in gammaretro-
viral vectors sufficient for in vivo protection and selec-
tion of the transduced mouse bone marrow cells fol-
lowing the treatment with O6-BG and TMZ has been
also studied to avoid insertional mutagenesis and other
consequences caused by strong enhancer elements [57].
The human mutant form of MGMTP140K is also used
in other gene therapies to increase the percentage of ge- 
ne-modified cells after transplantation, for example in
anti-retroviral therapy of human immunodeficiency
virus infection [58].
The data obtained in mice encourage further in-
vestigations in large animal models and clinical trials.
Thus, gene transfer of the mutant MGMT (e. g. P140K)
into hematopoietic stem cells provides a mechanism for 
the alkylating drug resistance and the selective expan-
sion of gene-modified cells in vivo. A possible clinical
application of this myeloprotective gene strategy is che-
moprotection that allows a dose escalation of the alkyla-
ting chemotherapy.
Unfortunately, at the moment the abovementioned
strategies are not in clinical trials in Ukraine, except for 
dose-dense regimens of the cancer chemotherapy and
combinations of alkylating agents. Hopefully, this re-
view will stimulate the scientists in Ukraine to study
the problem of improvement of the cancer chemothe-
rapy by using the alkylating agents.
Conclusions. The alkylating agents are frequently
used in the cancer chemotherapy, so the relative level
of expression of the DNA repair enzyme MGMT, which
repairs the O6-alkylguanine caused by these agents, in
tumor cells may determine the response to these drugs.
The modulation of the MGMT expression and activity
in tumor and normal cells is currently being investiga-
ted to improve the cancer therapy by using the alkyla-
ting agents. Two main approaches to the improvement
of such chemotherapy are discussed in the review. The
first one is an increase in the efficiency of cancer che-
motherapy due to the MGMT inactivation. The MGMT
gene transcription repression, RNA interference, and
the MGMT enzyme activity depletion by using the do-
se-dense cytotoxic chemotherapy drug schedule, a com-
bination of alkylating agents with/or without pseudo-
substrate inhibitors of MGMT are the strategies of this
approach. The second approach has been developed to
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protect normal cells from the toxic effect of the alky-
lating drugs. It also includes several strategies, namely
the drug dose reduction, the local drug administration
and the myeloprotective gene therapy, which implies the 
MGMT activation in bone marrow hematopoietic cells.
The results of preclinical and clinical researches
involving various aspects of the MGMT modulation
could provide prospects for therapy of melanoma, glio- 
ma and other cancer types irresponsive to the alkylating 
agents. A variety of strategies for improving the cancer
therapy have been studied in clinical trials in different
countries. Further studies are needed for successful cli-
nical use of developed strategies, and especially at least 
the MGMT expression analysis during the choice of al-
kylating drugs and therapy scheme for the patients with 
aggressive malignant tumours.
А. П. Яци ши на
Су часні підхо ди до по кра ще ня про ти пух лин ної 
хіміот е рапії з ви ко рис тан ням алкілу валь них спо лук: 
стан про бле ми в світі та в Україні
Ре зю ме
Aлкілу вальні спо лу ки час то за сто со ву ють у хіміот е рапії раку.
Вони алкілу ють ге ном ну ДНК по ба гать ох сай тах. Алкілу ван ня
гуаніну в по зиції О6 ци то ток сич не, має на й сильніший му та ген ний
потенціал, а та кож може спри чи ня ти роз ви ток вто рин них пух -
лин. Алкільні гру пи у по зиції O6 гуаніну ви да ля ють ся за до по мо гою 
ре па ра тив но го фер мен ту O6-ме тил гу анін-ДНК ме тил тран сфе -
ра зи (MGMT). Ефек тивність хіміот е рапії з ви ко рис тан ням O6-
алкілу валь них спо лук об ме же на експресією MGMT у ра ко вих клі-
ти нах та шкідли вим побічним ток сич ним впли вом у нор маль них
кліти нах. На разі  для по кра щен ня хіміот е рапії раку роз роб ля ють
різні підхо ди до мо ду ляції експресії та ак тив ності MGMT. До них
на ле жать два го лов них на прям ки, а саме – підви щен ня хіміочут -
ли вості ра ко вих клітин до алкілу валь них ліків і за хист нор маль -
них клітин від ток сич ної дії хіміот е рапії. Огляд зо се ред же но на
існу ю чих спро бах по кра щи ти хіміот е рапію зло якісних пух лин за
до по мо гою алкілу валь них спо лук як у світі, так і в Україні.
Клю чові сло ва: хіміот е рапія раку, стра тегії по кра щен ня
хіміот е рапії, алкілу вальні спо лу ки, O6-ме тил гу анін-ДНК ме тил -
тран сфе ра за (MGMT), ре па рація ДНК.
А. П. Яцы ши на
Сов ре мен ные под хо ды к улуч ше нию про ти во о пу хо ле вой 
хи ми о те ра пии с ис поль зо ва ни ем ал ки ли ру ю щих со е ди не ний: 
со сто я ние про бле мы в мире и в Укра и не
Ре зю ме
Алкилирующие со е ди не ния час то при ме ня ют в хи ми о те ра пии ра-
ка. Они ал ки ли ру ют ге ном ную ДНК по мно гим сай там. Алкилиро-
ва ние гу а ни на в по зи ции O6 ци то ток сич но, име ет силь ней ший му -
та ген ный по тен ци ал и мо жет при во дить к раз ви тию вто рич ных 
опу хо лей. Алкильные груп пы в по зи ции O6 гу а ни на уда ля ют ся с по- 
мощью ре па ра тив но го фер мен та O6-ме тил гу а нин-ДНК ме тил -
тран сфе ра зы (MGMT). Эффек тив ность хи ми о те ра пии с ис поль- 
зо ва ни ем O6-ал ки ли ру ю щих со е ди не ний огра ни че на экс прес си ей
MGMT в опу хо ле вых клет ках и не бла гоп ри ят ным по боч ным ток -
си чес ким де йстви ем в нор маль ных клет ках. В на сто я щее вре мя
для улуч ше ния хи ми о те ра пии рака раз ра ба ты ва ют ся раз ные под-
ходы к мо ду ля ции экс прес сии и ак тив нос ти MGMT. К ним при -
над ле жат два основ ных на прав ле ния, а имен но – уве ли че ние хи -
ми о чу встви тель нос ти ра ко вых кле ток к ал ки ли ру ю щим ле кар-
ствам и за щи та нор маль ных кле ток от по боч но го вли я ния хи мио-
те ра пии. Обзор со сре до то чен на су щес тву ю щих по пыт ках улуч -
шить хи ми о те ра пию зло ка чес твен ных опу хо лей с по мощью ал ки -
ли ру ю щих со е ди не ний как в мире, так и в Укра и не.
Клю че вые сло ва: хи ми о те ра пия рака, стра те гии улуч ше ния
хи ми о те ра пии, ал ки ли ру ю щие со е ди не ния, O6-ме тил гу а нин-ДНК
ме тил тран сфе ра за (MGMT), ре па ра ция ДНК.
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